RxDoctor Payments Data

Priya Balan

Medical-Surgical · Phoenix, AZNPI 1366015067

Payments from drug & device makers

$4,558in general payments, 2019–2025

Across 222 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$561
  • Alkermes, Inc.$463
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$318
  • Vanda Pharmaceuticals Inc.$307
  • Lundbeck LLC$234
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical-surgical providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$33,434
Medicare patients
42
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QelbreeViloxazine Hcl24$7,681
Aripiprazole113$3,734
Bupropion XlBupropion Hcl104$2,790
Quetiapine Fumarate173$2,449
Hydroxyzine Pamoate124$1,926
Buspirone Hcl109$1,276
Trazodone Hcl153$1,212
Lamotrigine140$1,161
Atomoxetine Hcl15$1,039
Hydroxyzine Hcl50$962
Mirtazapine103$934
Duloxetine Hcl50$715
Sertraline Hcl124$677
Prazosin Hcl26$613
Escitalopram Oxalate76$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Supernus Pharmaceuticals, Inc.Qelbree$165$7,68124 claims
Almatica Pharma LLCSertraline Hcl$170$677124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical-surgical providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other medical-surgical in Phoenix

Where these figures come from

Is this you, or does something look wrong? →